Ollin Biosciences raised $330 million in a Series B as it prepares pivotal testing for an eye therapy targeting diabetic macular edema and wet age-related macular degeneration. The funding is positioned as a run-up to Phase 3 studies, with the company emphasizing readiness for late-stage clinical execution. STAT reports that TCGX and ARCH Venture Partners co-led the round, alongside pension and crossover investors. The financing also underscores investor appetite for differentiated ophthalmology programs as companies gear up for regulatory milestones. The round follows earlier competitive positioning for Ollin’s Vabysmo challenger, signaling that capital markets are funding head-to-head momentum in retina.